Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase

Arzneimittelforschung. 1994 May;44(5):629-36.

Abstract

2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl, 2,3-dihydro-1H-pyrrolizine-5-yl)-acetic acid (ML 3000) is a dual inhibitor of the enzymes cyclo-oxygenase and 5-lipoxygenase in bovine and human thrombocytes and granulocytes. In animal experiments the compound has antiphlogistic, analgesic, antipyretic, antiasthmatic and antiaggregative activity at a dosage that causes no gastrointestinal damage.

MeSH terms

  • Acetates / pharmacology*
  • Animals
  • Arachidonic Acid / antagonists & inhibitors
  • Arachidonic Acid / pharmacology
  • Arthritis, Experimental / drug therapy
  • Benzoquinones
  • Blood Coagulation / drug effects
  • Bronchoconstriction / drug effects
  • Carrageenan
  • Cyclooxygenase Inhibitors / pharmacology*
  • Edema / chemically induced
  • Edema / prevention & control
  • Female
  • Guinea Pigs
  • In Vitro Techniques
  • Lipoxygenase Inhibitors / pharmacology*
  • Male
  • Mice
  • Mice, Inbred ICR
  • Pain Measurement / drug effects
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / pharmacology
  • Pyrroles / pharmacology*
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Yeast, Dried

Substances

  • Acetates
  • Benzoquinones
  • Cyclooxygenase Inhibitors
  • Lipoxygenase Inhibitors
  • Platelet Aggregation Inhibitors
  • Pyrroles
  • Arachidonic Acid
  • phenylbenzoquinone
  • Carrageenan
  • licofelone